Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Prepaid Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Prepaid Assets for 12 consecutive years, with $28.5 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets rose 19.61% to $28.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.5 million through Dec 2025, up 19.61% year-over-year, with the annual reading at $28.5 million for FY2025, 19.61% up from the prior year.
  • Prepaid Assets for Q4 2025 was $28.5 million at ImmunityBio, down from $32.9 million in the prior quarter.
  • The five-year high for Prepaid Assets was $32.9 million in Q3 2025, with the low at $283000.0 in Q2 2021.
  • Average Prepaid Assets over 5 years is $16.6 million, with a median of $21.3 million recorded in 2024.
  • The sharpest move saw Prepaid Assets skyrocketed 10713.07% in 2022, then plummeted 94.05% in 2024.
  • Over 5 years, Prepaid Assets stood at $3.0 million in 2021, then tumbled by 33.07% to $2.0 million in 2022, then soared by 1193.73% to $25.6 million in 2023, then decreased by 6.84% to $23.9 million in 2024, then grew by 19.61% to $28.5 million in 2025.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $28.5 million, $32.9 million, and $25.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.